ARQT stock forecast, quote, news & analysis
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs... Show more
Arcutis Biotherapeutics (ARQT) Stock Analysis: Pipeline Expansion Sparks Investor Interest
- Arcutis Biotherapeutics reported robust growth for its flagship dermatology drug ZORYVE in early 2026, driving positive sentiment.
- Company advanced Phase 2 trials for vitiligo and hidradenitis suppurativa, alongside launching ARQ-234 for atopic dermatitis.
- Analyst price target consensus stands at $29.00, signaling potential upside from current levels.
- Recent nationwide survey highlighted patient concerns with topical steroids, bolstering non-steroidal alternatives like ZORYVE.
- Stock experienced volatility, including an 11.8% pullback amid broader pipeline updates.
Current Market Snapshot
In recent weeks, Arcutis Biotherapeutics (ARQT) stock has navigated a mix of optimism and volatility amid expanding dermatology pipeline developments. Shares reflected investor enthusiasm for commercial progress with ZORYVE, tempered by short-term reactions to clinical updates. Trading volume spiked around key announcements, underscoring heightened interest in the company's shift toward broader immune-mediated skin condition treatments. Broader biotech sector dynamics and macroeconomic pressures have influenced the stock's trajectory, positioning ARQT at a pivotal juncture for momentum traders monitoring breakout potential.
AI Trading Bot Spotlight
The Day Trader: Momentum Trading, Slow Reaction V1, 60 min, (TA) is a Tickeron AI-powered trading bot designed for ARQT and similar momentum-driven stocks. Operating on a 60-minute timeframe, it employs technical analysis (TA) indicators to identify slow-reaction momentum setups, capturing gradual price accelerations while filtering out noise from rapid fluctuations. The strategy focuses on entry signals during confirmed uptrends, with built-in risk management to protect against reversals. Backtested performance highlights consistent gains in volatile biotech environments, making it suitable for day traders seeking automated, data-driven decisions. Consider integrating this bot into your strategy to streamline ARQT trades with precision.
Recent Developments Driving ARQT Price Action
Arcutis Biotherapeutics (ARQT), a biopharmaceutical company specializing in topical treatments for immune-mediated skin diseases, has seen its stock influenced by several key updates in the past 30 days. Central to recent price movements was the company's report on continued commercial growth for ZORYVE, its lead product for plaque psoriasis and atopic dermatitis. Early 2026 data showed expanding prescriptions and market penetration, fueling bullish sentiment as Arcutis positions ZORYVE as a steroid-free alternative amid growing patient concerns.
A nationwide survey released just days ago underscored widespread worries about topical steroid side effects, with nearly 9 in 10 patients expressing fears and 46 million Americans grappling with chronic skin conditions. This highlighted ZORYVE's appeal, contributing to positive investor reactions and supporting ARQT's upward momentum in recent sessions.
Pipeline expansion news further shaped trading dynamics. Arcutis outlined Phase 2 trials for ZORYVE in vitiligo and hidradenitis suppurativa, alongside initiating clinical development of ARQ-234 for atopic dermatitis. While these updates signaled long-term growth potential, they triggered an 11.8% stock decline in one session, as investors weighed execution risks against opportunities in underserved markets. The pullback reflected profit-taking and caution over development timelines in a competitive dermatology space.
Analyst coverage remained supportive, with a consensus price target of $29.00 as of mid-January 2026, implying significant upside. MarketBeat and other platforms noted "Buy" leanings, driven by revenue acceleration and a robust cash position. Broader industry tailwinds, including FDA priorities on innovative topicals, amplified these effects. However, biotech sector volatility—tied to interest rate sensitivities and peer performances—added downward pressure during risk-off periods.
Overall, these developments linked directly to price action: growth metrics and surveys lifted shares, while pipeline risks prompted dips, creating opportunities for momentum strategies attuned to news flow.
2026 Outlook and Key Factors to Monitor
As Arcutis Biotherapeutics progresses through 2026, investors should track ZORYVE's market share gains in psoriasis and atopic dermatitis, alongside Phase 2 readouts for vitiligo, hidradenitis suppurativa, and ARQ-234. Successful trial advancements could validate pipeline depth, supporting revenue diversification in the $15 billion U.S. dermatology market.
Key opportunities include capturing demand for non-steroidal therapies, bolstered by ongoing steroid safety scrutiny. Regulatory milestones, such as potential label expansions, will be critical, as will cash burn rates amid R&D investments. Competitive pressures from peers like Pfizer and Eli Lilly in immunology necessitate monitoring differentiation via topical delivery advantages.
Risks encompass clinical setbacks, reimbursement dynamics, and macroeconomic headwinds affecting biotech valuations. Strategic partnerships for commercialization could enhance scale. Consensus analyst targets around $29.00 reflect optimism, but execution on growth targets remains pivotal for sustained performance throughout the year.
ARQT in upward trend: price rose above 50-day moving average on June 09, 2026
ARQT moved above its 50-day moving average on June 09, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 01, 2026. You may want to consider a long position or call options on ARQT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on May 27, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for ARQT moved below the 200-day moving average on May 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARQT broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARQT entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.077) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). ARQT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (7.513) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology